Evotec Takes the Stage in Frankfurt With a Restructuring Story and a Gilead Payday

Evotec posts deep Q1 net loss of €121.9M, issues dilutive convertible bond, but strategic portfolio moves like Tubulis sale and cost-cutting offer a turnaround narrative; shares down 38% YTD.

Evotec’s management is heading to Frankfurt this month for the dbAccess European Champions Conference, carrying a packed agenda of explanations. After a first quarter that plunged deep into the red and a freshly placed convertible bond that has diluted existing holders, the mood among investors is decidedly mixed. The shares have clawed back some ground — up roughly 10 percent on the week to €5.18 and recapturing their 50-day moving average — but the year-to-date picture remains ugly, with a loss of about 38 percent.

The numbers from early May lay bare the scale of the challenge. First-quarter revenue came in at €156.6 million, while the adjusted operating result swung to a loss of €21.9 million, a figure the company attributes to one-off effects and currency headwinds. Zooming out to the net line, the damage is even starker: a net loss of €121.9 million, largely driven by €75 million in restructuring costs tied to the Horizon transformation program. Evotec has nonetheless confirmed its full-year guidance, betting that the cost-cutting and efficiency measures will start to feed through later in the year.

To fund the overhaul, Evotec raised €116.1 million through an unsecured convertible bond maturing in 2033, carrying a coupon of 2.625 percent and an initial conversion price of roughly €6.53. The move explicitly excluded shareholders’ pre-emptive rights, meaning any future conversion will dilute existing equity. That dilution risk is one reason the stock is trading at less than half the implied conversion price, a gap investors are pricing in as a discount for uncertainty.

Away from the financing drama, there are genuine strategic bright spots. Evotec has sold its minority stake in Tubulis to Gilead for around $100 million upfront, with up to $58 million more in milestone payments. That deal, along with the broader strategic review of the company’s portfolio, capital structure and long-term ownership — advised by Morgan Stanley and Moelis — gives the narrative a second layer. Meanwhile, the collaboration with Almirall has delivered its first preclinical development candidate, and new funding from the Gates Foundation is supporting tuberculosis research programs.

Operationally, the management team has also been reshuffled. Dr. Ingrid Müller took over as chief operating officer on May 1, with Claire Hinshelwood stepping into the finance chief role on the same date. Evotec’s liquidity position stands at €444.8 million, providing a cushion as the Horizon program runs its course.

Analysts see a wide range of outcomes. The 12-month consensus target sits at roughly €7, but individual estimates span from €4.40 to €10. Four analysts rate the stock a buy; none recommend selling — though BofA Securities clings to an underperform rating. The stock’s recent bounce, gaining over 11 percent in the past seven days to €5.24, suggests some investors are betting the restructuring will eventually pay off. But with the 52-week low of €4.14 still within striking distance, the risk of another leg down remains real.

The Frankfurt conference gives executives a chance to prove the turnaround is more than a hope. Investors will want granular detail on capacity utilization, cost control and the timeline for Horizon’s first tangible benefits. If the presentation comes across as vague, the stock could easily test support at the lows. If the roadmap is clear, the recent uptrend might just have legs. For now, Evotec is a story of two competing forces: the short-term pain of restructuring and the long-term optionality unlocked by deals like the Gilead transaction. The next few weeks will show which force wins out.